Finland – March 20, 2025
VTT Technical Research Centre of Finland has opened a new pilot line environment for medical devices in Oulu, Finland.
Business Award – March 19, 2025
The President and CEO of Camurus, Fredrik Tiberg, has been named the winner of The Arthur D. Little Nordic Life Science Award.
Biotech article – March 19, 2025
Understanding the science is one thing, but being able to manufacture T-cell therapies at scale is a different matter. TCR-T cell therapies offer a path forward at a fraction of the cost and time of manufacturing a living cell as a product.
Business Award – March 18, 2025
The gala, organized by the Women in Business network, highlights female role models and works towards a more gender-equal corporate sector.
Biotech Business – March 18, 2025
The FDA has approved the company’s IND application to initiate the Phase I/II study Oncorella-1.
Biotech Business – March 18, 2025
The US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need.
Advertisement
Biotech Business – March 18, 2025
The FDA has approved the company’s IND application to initiate the Phase I/II study Oncorella-1.
CDMO – March 17, 2025
The company has announced the authorization of its Clinical Trial Application (CTA) from the regulatory authorities in four European countries under the European Union’s (EU) harmonised framework, for VIDAR-1, with Germany acting as the reference state.
Clinical Trials – February 28, 2025
Evaxion Biotech will further enhance the data package from its ongoing phase 2 trial with the company’s lead asset EVX-01 by extending the trial from two to three years.
Clinical Trials – February 24, 2025
Medivir has presented positive, final data from the phase 1b / 2a study of fostroxacitabine bralpamide (fostrox) + Lenvima in advanced liver cancer (hepatocellular carcinoma/HCC) at the EASL (European Association for the Study of the Liver) Liver Cancer Summit in Paris, France.
Clinical Trials – January 29, 2025
Herantis Pharma has announced an update of the ongoing Phase 1b clinical trial of HER-096.
Clinical Trials – January 14, 2025
Orexo has announced positive topline results from the clinical study OX640-002.
CDMO – March 17, 2025
The company has announced the authorization of its Clinical Trial Application (CTA) from the regulatory authorities in four European countries under the European Union’s (EU) harmonised framework, for VIDAR-1, with Germany acting as the reference state.
Agreement – March 17, 2025
The two companies have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology.
Acquisition – March 17, 2025
EsoBiotec is a biotechnology company focusing on in vivo cell therapies that has demonstrated promising early clinical activity.
Financing – March 12, 2025
This decision by the Board of Directors of Peptonic Medical is an extraordinary measure following a prolonged liquidity challenge and is intended to create the conditions for a stable and profitable business, they state.
Business article – March 12, 2025
Boule Diagnostics announces the decision to close the BM950 project due to newly identified technical issues that have significantly impacted the project’s time to market and overall profitability.
MedTech Business – March 6, 2025
Bactiguard has conducted an analysis of the market potential and partnership opportunities for its infection prevention technology.
Agreement – March 14, 2025
This collaboration aims to advance the discovery and development of new therapeutic solutions targeting G protein-coupled receptors (GPCRs), ion channels, transporters and other integral membrane proteins in therapeutic areas such as mental health and cardio-renal-metabolic diseases.
Biotech Business – March 10, 2025
The company has secured a financing round of EUR 19 million, part of which was raised in Europe and part in Australia, to clinically develop its innovative immune therapy for cancer.
Biotech Business – March 7, 2025
The two companies have announced the availability of SELARSDI injection in the US for the treatment of psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis.
Science Award – March 12, 2025
Professor Kirsi Pietiläinen, Professor of Clinical Metabolism at the Faculty of Medicine, University of Helsinki, receives the prize for her outstanding work in clinical metabolism.
Financing – March 3, 2025
The donation from Mrs Berta Kamprad Foundation is the largest donation to Lund University since its foundation in 1666.
Science Award – February 18, 2025
Miriam Merad is awarded the Sjöberg Prize, worth USD one million, for her discovery of new targets for cancer therapies in the immune system.
Stryker
The Junior Field Service Engineer is primarily responsible to maintain professional and profitable repair and preventive maintenance service business on Stryker’s products while ensuring compliance with the quality system and manufacturer specifications.
Stryker
As Senior Manager Marketing, you will manage a talented team of Product & Marketing Managers and drive market share growth for our Neurovascular business in EMEA – through the formulation and execution of strategic marketing plans.
Stryker
As Territory Sales Manager, you will help us deliver on our mission of making healthcare better by promoting and selling Stryker’s Surgical Technologies product portfolio.
BHS Logistics
BHS Logistics is a modern transport company focused on the customers’ wishes and needs for large capacity and flexibility, as well as the secure storage, handling, and transport of goods.
Eltronic A/S
Eltronic A/S is Denmark’s leading automation company, with over 25 years of experience in implementing production systems and automation solutions. The company’s goal is to be the preferred partner for its customers while enhancing their global competitiveness and sustainability.
Scandinavian CRO
Scandinavian CRO is in an exciting expansion phase, and we’re looking for a new Business Development (BD) Manager to strengthen our team.
In a new job – March 13, 2025
Cellevate has appointed Christel Fenge as Chief Technology Officer (CTO) and member of the management team.
In a new job – March 10, 2025
Ulrika Hammarström will lead the international Aurevia CRO (Contract Research Organization) team.
In a new job – March 7, 2025
Anna Hellergård has a master’s degree in molecular cell biology with a specialization in AI with a focus on biomedicine and digital health transformation.
Career choice – March 14, 2025
Charlotte Schönbeck has always been inquisitive and as sales specialist she gets to work with many different life science professionals. She learns something new from all of them by working together through their individual challenges to find the best solution.
Careers article – January 9, 2025
Getting back to work after a long and relaxing holiday can be quite hard. Here is some advice to make things easier.
Biotech Business – December 3, 2024
Alligator Bioscience is sharpening its primary focus on its lead asset mitazalimab, and, given current capital restraints, plans to adjust the size of its organization and scope of operations to reflect that.
Nobel Prize Laureate – December 12, 2024
Victor Ambros, Professor of Molecular Medicine and the Silverman Chair in Natural Sciences at the University of Massachusetts Chan Medical School, is one of this year’s winners of the Nobel Prize in Physiology or Medicine.
Nobel Prize Laureate – December 10, 2024
More than three decades after their discovery of microRNA, Professor Gary Ruvkun received the “mythic call” from Stockholm to learn that he’d been awarded the Nobel Prize in Physiology or Medicine alongside his erstwhile colleague Victor Ambros.
Profiles in Science – September 10, 2024
Anna Wedell, Professor and Research Group Leader of the group Inborn Errors of Endocrinology and Metabolism at Karolinska Institutet and Director of the new Precision Medicine Center Karolinska, explains how research in rare diseases has evolved due to new technologies, and emphasizes that identifying synergies is essential for diagnosing and treating these conditions.
This site uses cookies
